Barbara Voith

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

Dagmar Kubitza, Michael Becka, Barbara Voith et al. · Clinical Pharmacology & Therapeutics · 2005 · 652 citations

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

Dagmar Kubitza, Michael Becka, Georg Wensing et al. · European Journal of Clinical Pharmacology · 2005 · 648 citations

Therapeutic Drug Monitoring, Pharmacology, Clinical Pharmacology +5

A Mechanistic Approach for the Scaling of Clearance in Children

Andrea N. Edginton, Walter Schmitt, Barbara Voith et al. · Clinical Pharmacokinetics · 2006 · 216 citations

Child Psychology, Social Skills, Child Health +11

Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban an oral, direct Factor Xa inhibitor in healthy subjects

Wolfgang Mueck, Michael Becka, Dagmar Kubitza et al. · International Journal of Clinical Pharmacology and Therapeutics · 2007 · 178 citations

First Assessment in Humans of the Safety, Tolerability, Pharmacokinetics, and Ex Vivo Pharmacodynamic Antimalarial Activity of the New Artemisinin Derivative Artemisone

Johannes Nagelschmitz, Barbara Voith, Georg Wensing et al. · Antimicrobial Agents and Chemotherapy · 2008 · 95 citations · Full text

Medicinal Chemistry, Allergy, Bay 44-9585 +14